Glazer Capital LLC’s Jasper Therapeutics JSPR Stock Holding History

Glazer Capital LLC’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,940	Closed	-$590K	–	956
2021 Q2	$590K	Sell	5,940 -99,060	-94%	-$9.84M	0.01%	576
2021 Q1	$10.4M	Sell	105,000 -2,313	-2%	-$235K	0.15%	207
2020 Q4	$10.7M	Buy	107,313 +3,420	+3%	+$340K	0.38%	85
2020 Q3	$10.3M	Buy	103,893 +56,248	+118%	+$5.62M	0.5%	64
2020 Q2	$4.76M	Hold	47,645	–	–	0.34%	74
2020 Q1	$4.55M	Buy	+47,645	New	+$4.66M	0.3%	74

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Glazer Capital LLC's JSPR Position: Q3 2021 in Review

Glazer Capital LLC sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 5,940 shares — an estimated $590K sold.

Glazer Capital LLC first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $10.7M in Q4 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Glazer Capital LLC reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Glazer Capital LLC sold 5,940 Jasper Therapeutics shares in Q3 2021, an estimated $590K.
Glazer Capital LLC first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Glazer Capital LLC's Jasper Therapeutics position peaked at $10.7M in Q4 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Glazer Capital LLC's 13F filing for Q3 2021, filed 15 Nov 2021.